BNP Paribas Asset Management
DNLI icon

BNP Paribas Asset Management’s Denali Therapeutics DNLI Stock Holding History

BNP Paribas Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9M Buy
1,355,514
+1,059,011
+357% +$21.8M 0.03% 441
2026
Q1 		$5.69M Sell
296,503
-2,289
-0.8% -$45.5K 0.01% 831
2025
Q4 		$4.93M Buy
298,792
+297,521
+23,408% +$5.02M 0.01% 846
2025
Q3 		$18K Buy
1,271
+132
+12% +$1.9K ﹤0.01% 1427
2025
Q2 		$16K Buy
+1,139
New +$16K ﹤0.01% 1592

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's DNLI Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Denali Therapeutics (DNLI) stake by 357% in Q2 2026, buying an estimated $21.8M and bringing the position to 1,355,514 shares worth $34.9M. The position accounts for 0.03% of the portfolio, ranked #441.

BNP Paribas Asset Management first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • BNP Paribas Asset Management held 1,355,514 shares of Denali Therapeutics worth $34.9M as of Q2 2026.
  • BNP Paribas Asset Management bought 1,059,011 Denali Therapeutics shares in Q2 2026, an estimated $21.8M.
  • Denali Therapeutics made up 0.03% of BNP Paribas Asset Management's portfolio in Q2 2026, its #441 holding.
  • BNP Paribas Asset Management first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.